Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Felzartamab (MOR202) in Anti-PLA2R Positive Membranous Nephropathy
NCT04733040Phase 2Completed
- Sponsor
- Biogen
- Start
- Jan 2021
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of felzartamab in membranous nephropathy (MN), sponsored by Biogen. Started Jan 2021; status: completed.
02
Drugs
felzartamab
03
Conditions
membranous nephropathy (MN)
Beyond the preview
Go deeper on NCT04733040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04733040.